MARKET

BLRX

BLRX

Biolinerx
NASDAQ
2.670
+0.010
+0.38%
Closed 15:21 03/13 EDT
OPEN
2.700
PREV CLOSE
2.660
HIGH
2.700
LOW
2.612
VOLUME
7.43K
TURNOVER
--
52 WEEK HIGH
7.77
52 WEEK LOW
2.300
MARKET CAP
11.62M
P/E (TTM)
-2.0583
1D
5D
1M
3M
1Y
5Y
1D
BioLineRx to release audited 2025 annual results and host conference call
Reuters · 24m ago
BioLineRx to Report 2025 Annual Results on March 23, 2026
PR Newswire · 27m ago
Weekly Report: what happened at BLRX last week (0309-0313)?
Weekly Report · 1h ago
Weekly Report: what happened at BLRX last week (0302-0306)?
Weekly Report · 03/09 09:52
Weekly Report: what happened at BLRX last week (0223-0227)?
Weekly Report · 03/02 09:52
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 02/26 21:05
BioLineRx Wins Arbitration Ruling in Motixafortide Licensing Dispute
TipRanks · 02/23 15:19
Arbitrator Issues Final Award To BioLineRx, Denies All Claims By Biokine Therapeutics; Biokine To Pay Expenses And Legal Fees
Benzinga · 02/23 14:36
More
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Webull offers BioLine RX Ltd - ADR stock information, including NASDAQ: BLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BLRX stock methods without spending real money on the virtual paper trading platform.